TY - JOUR
T1 - Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis
AU - Mowatt, Graham
AU - N'Dow, James
AU - Vale, Luke
AU - Nabi, Ghulam
AU - Boachie, Charles
AU - Cook, Jonathan A.
AU - Fraser, Cynthia
AU - Griffiths, T. R. Leyshon
AU - Aberdeen Technology Assessment
PY - 2011/1
Y1 - 2011/1
N2 - Objectives: The aim of this study was to assess the test performance and clinical effectiveness of photodynamic diagnosis (PDD) compared with white light cystoscopy (WLC) in people suspected of new or recurrent bladder cancer.Methods: A systematic review was conducted of randomized controlled trials (RCTs), nonrandomized comparative studies, or diagnostic cross-sectional studies comparing PDD with WLC. Fifteen electronic databases and Web sites were searched (last searches April 2008). For clinical effectiveness, only RCTs were considered.Results: Twenty-seven studies (2,949 participants) assessed test performance. PDD had higher sensitivity than WLC (92 percent, 95 percent confidence interval [Cl], 80-100 percent versus 71 percent, 95 percent Cl, 49-93 percent) but lower specificity (57 percent, 95 percent Cl, 36-79 percent versus 72 percent, 95 percent Cl, 47-96 percent). For detecting higher risk tumors, median range sensitivity of PDD (89 percent [6-100 percent]) was higher than WLC (56 percent [0-100 percent]) whereas for lower risk tumors it was broadly similar (92 percent [20-95 percent] versus 95 percent [8-100 percent]). Four RCTs (709 participants) using 5-aminolaevulinic acid (5-ALA) as the photosensitising agent reported clinical effectiveness. Using PDD at transurethral resection of bladder tumor (TURBT) resulted in fewer residual tumors at check cystoscopy (relative risk [RR], 0.37, 95 percent Cl, 0.20-0.69) and longer recurrence-free survival (RR, 1.37, 95 percent Cl, 1.18-1.59), compared with WLC.Conclusions: PDD detects more bladder tumors than WLC, including more high-risk tumors. Based on four RCTs reporting clinical effectiveness, 5-aminolaevulinic acid mediated PDD at TURBT facilitates a more complete resection and prolongs recurrence-free survival.
AB - Objectives: The aim of this study was to assess the test performance and clinical effectiveness of photodynamic diagnosis (PDD) compared with white light cystoscopy (WLC) in people suspected of new or recurrent bladder cancer.Methods: A systematic review was conducted of randomized controlled trials (RCTs), nonrandomized comparative studies, or diagnostic cross-sectional studies comparing PDD with WLC. Fifteen electronic databases and Web sites were searched (last searches April 2008). For clinical effectiveness, only RCTs were considered.Results: Twenty-seven studies (2,949 participants) assessed test performance. PDD had higher sensitivity than WLC (92 percent, 95 percent confidence interval [Cl], 80-100 percent versus 71 percent, 95 percent Cl, 49-93 percent) but lower specificity (57 percent, 95 percent Cl, 36-79 percent versus 72 percent, 95 percent Cl, 47-96 percent). For detecting higher risk tumors, median range sensitivity of PDD (89 percent [6-100 percent]) was higher than WLC (56 percent [0-100 percent]) whereas for lower risk tumors it was broadly similar (92 percent [20-95 percent] versus 95 percent [8-100 percent]). Four RCTs (709 participants) using 5-aminolaevulinic acid (5-ALA) as the photosensitising agent reported clinical effectiveness. Using PDD at transurethral resection of bladder tumor (TURBT) resulted in fewer residual tumors at check cystoscopy (relative risk [RR], 0.37, 95 percent Cl, 0.20-0.69) and longer recurrence-free survival (RR, 1.37, 95 percent Cl, 1.18-1.59), compared with WLC.Conclusions: PDD detects more bladder tumors than WLC, including more high-risk tumors. Based on four RCTs reporting clinical effectiveness, 5-aminolaevulinic acid mediated PDD at TURBT facilitates a more complete resection and prolongs recurrence-free survival.
KW - Systematic review
KW - Meta-analysis
KW - Diagnostic tests
KW - Bladder cancer
KW - FLUORESCENCE CYSTOSCOPY
KW - TRANSURETHRAL RESECTION
KW - 5-AMINOLEVULINIC ACID
KW - RECURRENCE
KW - CHEMOTHERAPY
KW - INSTILLATION
KW - CARCINOMA
KW - ENDOSCOPY
KW - RISK
U2 - 10.1017/S0266462310001364
DO - 10.1017/S0266462310001364
M3 - Article
SN - 0266-4623
VL - 27
SP - 310
JO - International Journal of Technology Assessment in Health Care
JF - International Journal of Technology Assessment in Health Care
IS - 1
ER -